PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance

Company Update - PROCEPT BioRobotics announced FDA 510(k) clearance for its next-generation HYDROS Robotic System, marking a significant milestone in the adoption of Aquablation therapy [1] - The HYDROS Robotic System incorporates major technological innovations developed over years of research and is expected to drive the company's next growth phase [2] - The system is designed to enhance productivity, improve surgeon experience, and deliver precise, consistent treatment plans, with a full market release anticipated within the current quarter [4] Product Features - The HYDROS Robotic System features FirstAssist AI treatment planning, advanced image guidance, and robotic resection, aiming to provide superior clinical outcomes [5] - It integrates digital cystoscopy, next-generation ultrasound imaging, and dual high-definition touchscreens for improved anatomy visualization [6] - The system uses a heat-free waterjet to remove obstructive tissue while protecting vital structures, ensuring efficient and predictable execution across various prostate sizes [7] Industry Outlook - The global BPH treatment devices market was valued at $1.42 billion in 2022 and is projected to grow at a CAGR of 8.9% from 2023 to 2030 [8] - Growth is driven by technological advancements, increasing prevalence of urological illnesses, and rising patient awareness of minimally invasive treatment options [8][9] - Demand for innovative, minimally invasive technologies like Aquablation therapy is expected to rise due to fewer side effects and faster recovery times compared to traditional surgical methods [9] Stock Performance - PRCT's shares have gained 99% year-to-date, significantly outperforming the industry's 9.4% rise and the S&P 500's 17.8% increase [10]